Antibody Discovery Workflow Antibody Screening
Therapeutic antibodies are one of the fastest-growing classes of drugs with the promise of better specificity and safety. Successful antibody discovery campaigns take advantage of technologies that allow for rapid identification and characterization of candidate molecules with superior target reactivity and optimized functionality.
The iQue® Advanced Flow Cytometry Platform saves you time, resources, and cost across the biologics discovery workflow.
- Screen antibodies generated from hybridomas and primary B-cell cultures as well as arrayed libraries from display technologies
- Identify candidates with the desired biological outcome by evaluating cell health, function and cytokine release in the same assay
- Rapidly identify lead clones by simultaneously evaluating suspension CHO cells and quantifying their secreted proteins
Click below to see how the iQue® Advanced Flow Cytometry Platform streamlines the three biologics discovery workflow steps antibody screening, functional profiling, and bioprocessing.
How the iQue® Advanced Flow Cytometry Platform is Changing the Way We Obtain Compelling Data
“In-solution, cell-based assays are the way forward and the ability to do so with the iQue® Advanced Flow Cytometry Platform in a 384-well high-throughput format has been extremely useful to us. We can now use one third of the materials and screen 4 times more antibody clones in the same amount of time, obtaining more compelling data for ourselves and our clients. – Andrea Gorlani, PhD, Scientist ModiQuest Research
The iQue® Advanced Flow Cytometry Platform utilizes a unique and rapid, air-gap-delimited sampling technology paired to a no-adjustment, flow-based detection engine and powerful, easy-to-use iQue Forecyt® Software for assay management and analysis.
More data than ELISAs
Unlike ELISAs, which can only report on binding to single antigens and require large amounts of the target protein to coat entire wells, the iQue® Advanced Flow Cytometry Platform is able to simultaneously acquire data on multiple biological readouts and with much less protein. Using differential fluorescent labeling, multiple cell types and a range of cellular parameters can be assessed all in the same well, quickly generating a rich, highly-informative data set. And because multiple target proteins can be presented on beads or on the cell surface, precious reagents are conserved, reducing costs.
Assays in more relevant, native environments
Because the iQue® Advanced Flow Cytometry Platform supports cell-based assays, target proteins can be presented on the cell surface instead of coated on the wells of a plate. By placing the target in its native conformation, results are more likely to be biologically relevant and better indicators of what will happen in vivo.
Faster than traditional flow
By sampling only microliters from each well and delivering an air-gap-delimited flow of samples to the detectors, the iQue® Advanced Flow Cytometry Platform converts the traditional low throughput, time-consuming flow cytometry approach into a high throughput process capable of rapidly driving the antibody screening process forward. The end result is a data-rich snapshot of the molecular events occurring in each well that can take less than five minutes for a 96-well plate and under 20 minutes for a 384-well plate.
Get more relevant data on your antibodies faster with the iQue® Advanced Flow Cytometry Platform
- Gain more relevant insights by screening targets in their native conformations on the cell surface.
- Expand what each assay tells you by assessing binding against multiple targets simultaneously.
- Increase the scale of your screens through the ability to use much less of each target protein.
- Amplify what you learn by combining binding assays with functional assays.